| 中文名稱:ASTX660 | 英文名稱:ASTX660 |
| CAS:1799328-86-1 | 品牌: 一研 |
| 保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
| Cas : 1799328-86-1 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
ASTX660 | 10mM*1mLinDMSO 1mg 5mg 10mg 25mg | 1799328-86-1 | EY-Y0165164 |
Cas No.1799328-86-1
別名 N/A
化學(xué)名 N/A
分子式 C30H42FN5O3

分子量 539.68
溶解度 DMSO : ≥ 50 mg/mL (92.65 mM)
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).
ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660[1].
In HCC1806 xenografts in mice, ASTX660 (daily oral treatment) causes moderate tumor growth inhibition but not regression[1].
[1]. Tomoko Smyth, et al. Abstract 1287: The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo. Cancer Res 2016;76(14 Suppl).
| 成立日期 | 2014-06-05 (13年) | 注冊(cè)資本 | 100 |
| 員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
| 主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| ¥900 |
VIP3年
|
湖北楚昌生物醫(yī)藥科技有限公司
|
2026-07-15 | |
| 詢價(jià) |
VIP11年
|
上海芮暉化工科技有限公司
|
2026-07-15 | |
| 詢價(jià) |
VIP5年
|
TargetMol中國(陶術(shù)生物)
|
2026-06-29 | |
| ¥239.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2026-06-10 | |
| 詢價(jià) |
VIP8年
|
臺(tái)州市科瑞生物技術(shù)有限公司
|
2025-07-31 |